Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Shares Outstanding (2016 - 2025)

Rocket Pharmaceuticals' Shares Outstanding history spans 9 years, with the latest figure at $108.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1.75% year-over-year to $108.3 million; the TTM value through Dec 2025 reached $108.3 million, up 1.75%, while the annual FY2025 figure was $108.3 million, 1.75% up from the prior year.
  • Shares Outstanding for Q4 2025 was $108.3 million at Rocket Pharmaceuticals, roughly flat from $108.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $108.3 million in Q4 2025 and bottomed at $62.0 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $85.3 million (2023), against an average of $84.2 million.
  • The largest annual shift saw Shares Outstanding skyrocketed 32.88% in 2023 before it rose 1.08% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $64.5 million in 2021, then increased by 22.66% to $79.1 million in 2022, then increased by 14.1% to $90.3 million in 2023, then rose by 17.91% to $106.5 million in 2024, then rose by 1.75% to $108.3 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Shares Outstanding are $108.3 million (Q4 2025), $108.2 million (Q3 2025), and $107.9 million (Q2 2025).